FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W166152792> ?p ?o ?g. }

• W166152792 endingPage "40" @default.
• W166152792 startingPage "129" @default.
• W166152792 abstract "This study assessed the activity and tolerability of an HIV-protease inhibitor, saquinavir, alone or in combination with zidovudine. A total of 92 previously untreated HIV-infected patients with CD4 cell counts < 300 cells/mm3 participated in a parallel, randomized double-blind study. Patients were randomized to receive one of five treatments, each three times a day: 600 mg of saquinavir; 200 mg of zidovudine; 75, 200 or 600 mg of saquinavir in combination with 200 mg of zidovudine. The primary treatment period was 16 weeks, with monthly extensions in patients who did not show major disease progression or toxicity. The main measures of the efficacy of therapy used were changes in CD4 cell counts and in the concentration of HIV-1 RNA in the plasma (as determined by quantitative polymerase chain reaction). The 600 mg dose of saquinavir in combination with zidovudine induced a 1.6 log (after 4 weeks) and a 0.7 log (after 16 weeks) median reduction in plasma RNA concentration; this reduction was greater than those seen in the other four treatment groups. The combination of 600 mg of saquinavir with zidovudine also resulted in a larger and more sustained improvement in the CD4 cell count than either saquinavir or zidovudine monotherapy or the other combination therapies. In the group receiving 200 mg of saquinavir in combination with zidovudine, the maximal median change in CD4 cell count occurred at week 2 (85 cells/mm3), and by week 16 had fallen to 15 cells/mm3. In the group receiving 600 mg of saquinavir plus zidovudine, the median change in CD4 cell count remained high for the 16-week period (median change of 48 cells/mm3 at week 2 and 61 cells/mm3 at week 16). Saquinavir was safe and very well tolerated, either alone or in combination with zidovudine. The incidence of adverse events was greater in the four groups receiving zidovudine therapy, and all the most commonly reported adverse events have previously been associated with zidovudine therapy. Few changes in laboratory values occurred during the study, except for known zidovudine-associated toxicities. The most frequent abnormalities were raised aspartate aminotransferase and alanine aminotransferase levels, depressed calcium levels, and abnormally high or low phosphate levels. Despite the low oral bioavailability of saquinavir, combined virological and immunological data show definite antiviral activity in vivo for the combination of saquinavir at 600 mg plus zidovudine at 200 mg (each three times daily). The combination of drugs with different mechanisms of action represents an advance in the treatment of HIV infection." @default.
• W166152792 created "2016-06-24" @default.
• W166152792 creator A5000968576 @default.
• W166152792 creator A5012360574 @default.
• W166152792 creator A5017481279 @default.
• W166152792 creator A5021984756 @default.
• W166152792 creator A5047901848 @default.
• W166152792 creator A5047906523 @default.
• W166152792 creator A5057063044 @default.
• W166152792 creator A5064623739 @default.
• W166152792 creator A5068517502 @default.
• W166152792 creator A5072985597 @default.
• W166152792 creator A5073230749 @default.
• W166152792 creator A5078129526 @default.
• W166152792 creator A5078602822 @default.
• W166152792 creator A5087095797 @default.
• W166152792 creator A5090568505 @default.
• W166152792 date "1996-08-01" @default.
• W166152792 modified "2023-09-27" @default.
• W166152792 title "A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection." @default.
• W166152792 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11322246" @default.
• W166152792 hasPublicationYear "1996" @default.
• W166152792 type Work @default.
• W166152792 sameAs 166152792 @default.
• W166152792 citedByCount "10" @default.
• W166152792 countsByYear W1661527922018 @default.
• W166152792 crossrefType "journal-article" @default.
• W166152792 hasAuthorship W166152792A5000968576 @default.
• W166152792 hasAuthorship W166152792A5012360574 @default.
• W166152792 hasAuthorship W166152792A5017481279 @default.
• W166152792 hasAuthorship W166152792A5021984756 @default.
• W166152792 hasAuthorship W166152792A5047901848 @default.
• W166152792 hasAuthorship W166152792A5047906523 @default.
• W166152792 hasAuthorship W166152792A5057063044 @default.
• W166152792 hasAuthorship W166152792A5064623739 @default.
• W166152792 hasAuthorship W166152792A5068517502 @default.
• W166152792 hasAuthorship W166152792A5072985597 @default.
• W166152792 hasAuthorship W166152792A5073230749 @default.
• W166152792 hasAuthorship W166152792A5078129526 @default.
• W166152792 hasAuthorship W166152792A5078602822 @default.
• W166152792 hasAuthorship W166152792A5087095797 @default.
• W166152792 hasAuthorship W166152792A5090568505 @default.
• W166152792 hasConcept C126322002 @default.
• W166152792 hasConcept C142462285 @default.
• W166152792 hasConcept C159047783 @default.
• W166152792 hasConcept C168563851 @default.
• W166152792 hasConcept C197934379 @default.
• W166152792 hasConcept C2776452011 @default.
• W166152792 hasConcept C2776937687 @default.
• W166152792 hasConcept C2776999253 @default.
• W166152792 hasConcept C2778375690 @default.
• W166152792 hasConcept C2780216070 @default.
• W166152792 hasConcept C2780727368 @default.
• W166152792 hasConcept C2781143361 @default.
• W166152792 hasConcept C2993143319 @default.
• W166152792 hasConcept C3013748606 @default.
• W166152792 hasConcept C71924100 @default.
• W166152792 hasConcept C90924648 @default.
• W166152792 hasConcept C98274493 @default.
• W166152792 hasConceptScore W166152792C126322002 @default.
• W166152792 hasConceptScore W166152792C142462285 @default.
• W166152792 hasConceptScore W166152792C159047783 @default.
• W166152792 hasConceptScore W166152792C168563851 @default.
• W166152792 hasConceptScore W166152792C197934379 @default.
• W166152792 hasConceptScore W166152792C2776452011 @default.
• W166152792 hasConceptScore W166152792C2776937687 @default.
• W166152792 hasConceptScore W166152792C2776999253 @default.
• W166152792 hasConceptScore W166152792C2778375690 @default.
• W166152792 hasConceptScore W166152792C2780216070 @default.
• W166152792 hasConceptScore W166152792C2780727368 @default.
• W166152792 hasConceptScore W166152792C2781143361 @default.
• W166152792 hasConceptScore W166152792C2993143319 @default.
• W166152792 hasConceptScore W166152792C3013748606 @default.
• W166152792 hasConceptScore W166152792C71924100 @default.
• W166152792 hasConceptScore W166152792C90924648 @default.
• W166152792 hasConceptScore W166152792C98274493 @default.
• W166152792 hasIssue "3" @default.
• W166152792 hasLocation W1661527921 @default.
• W166152792 hasOpenAccess W166152792 @default.
• W166152792 hasPrimaryLocation W1661527921 @default.
• W166152792 hasRelatedWork W166152792 @default.
• W166152792 hasRelatedWork W1965485929 @default.
• W166152792 hasRelatedWork W1981568901 @default.
• W166152792 hasRelatedWork W2049173604 @default.
• W166152792 hasRelatedWork W2061065985 @default.
• W166152792 hasRelatedWork W2170109565 @default.
• W166152792 hasRelatedWork W2339827976 @default.
• W166152792 hasRelatedWork W2396610918 @default.
• W166152792 hasRelatedWork W2399861845 @default.
• W166152792 hasRelatedWork W2415569009 @default.
• W166152792 hasVolume "1" @default.
• W166152792 isParatext "false" @default.
• W166152792 isRetracted "false" @default.
• W166152792 magId "166152792" @default.
• W166152792 workType "article" @default.